Abstract Alzheimer's disease (AD), the most common cause of adult-onset dementia is
characterized by a progressive decline of cognitive functions accompanied by behavioral …

Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition
with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) …

Objective: To examine the role of butyrylcholinesterase (BuChE) in cholinergic signaling and
neurologic conditions, such as Alzheimer's disease (AD). The rationale for inhibiting …

A common feature in the Alzheimer's disease (AD) brain is the presence of
acetylcholinesterase (AChE) which is commonly associated with β-amyloid plaques and …

Acetylcholine (ACh) is one of the most important neurotransmitters in the central cholinergic
system; it specifically binds to muscarinic and nicotinic receptors and is degraded by …

Alzheimer's disease (AD) is a common progressive neurodegenerative disorder associated
with cholinergic neurons degeneration. The blood–brain barrier (BBB) not only provides …

Alzheimer disease (AD) and Parkinson disease (PD) are the most common
neurodegenerative disorders. For both diseases, early intervention is thought to be essential …

Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …

The amyloid precursor protein (APP), presenilin 1 (PS1), amyloid beta (Aβ), and GSK3 are
the effectors, which are significantly associated with progression of Alzheimer's Disease …

Abstract p75 neurotrophin receptor (p75NTR) signaling pathways substantially overlap with
degenerative networks active in Alzheimer disease (AD). Modulation of p75NTR with the first …